For example, Canale et al. reported that TP53 mutations are independent predictors of poor prognosis in EGFR-mutated NSCLC and are significantly connected to reduced PFS and OS in patients receiving first-line EGFR-TKIs [29]. Here, EGFR is linked to non-small cell lung carcinoma.